SDGR (Schrodinger, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SDGR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Rachit Jain | EVP & CFO | Sell | — | — |
| 2026-06-29 | Richard Friesner | Director | G | — | — |
| 2026-06-23 | ARUN OBEROI | Director | A | — | — |
| 2026-06-23 | Jeffrey Chodakewitz | Director | A | — | — |
| 2026-06-23 | GARY L GINSBERG | Director | A | — | — |
| 2026-06-23 | Nancy Thornberry | Director | A | — | — |
| 2026-06-23 | Gary Sender | Director | A | — | — |
| 2026-06-23 | Bridget A van Kralingen | Director | A | — | — |
| 2026-06-23 | Richard Friesner | Director | A | — | — |
| 2026-06-23 | Rosana Kapeller-Libermann | Director | A | — | — |
| 2026-06-23 | Michael Lynton | Director | A | — | — |
| 2026-04-17 | Rachit Jain | EVP & CFO | Sell | — | — |
| 2026-04-17 | Ramy Farid | President & CEO | MIXED | — | — |
| 2026-03-06 | Rachit Jain | EVP & CFO | Sell | — | — |
| 2026-03-06 | Ramy Farid | President & CEO | Sell | — | — |
| 2026-03-06 | Jenny Herman | CAO | Sell | — | — |
| 2026-03-06 | Karen Akinsanya | See Remarks | Sell | — | — |
| 2026-03-06 | Robert Lorne Abel | See Remarks | Sell | — | — |
| 2026-03-06 | Kenneth Patrick Lorton | EVP, CTO & COO, Software | Sell | — | — |
| 2026-03-06 | Yvonne Tran | EVP, CLO & CPO | Sell | — | — |
| 2026-03-03 | Kenneth Patrick Lorton | EVP, CTO & COO, Software | A | — | — |
| 2026-03-03 | Rachit Jain | EVP & CFO | A | — | — |
| 2026-03-03 | Karen Akinsanya | See Remarks | MIXED | — | — |
| 2026-03-03 | Robert Lorne Abel | See Remarks | A | — | — |
| 2026-03-03 | Jenny Herman | CAO | A | — | — |
| 2026-03-03 | Mannix Vartan Aklian | See Remarks | A | — | — |
| 2026-03-03 | Yvonne Tran | EVP, CLO & CPO | A | — | — |
| 2026-03-03 | Ramy Farid | President & CEO | MIXED | — | — |
| 2026-03-03 | Richard Friesner | Director | M | — | — |
| 2026-02-12 | Kenneth Patrick Lorton | EVP, CTO & COO, Software | Sell | — | — |
| 2026-02-12 | Yvonne Tran | EVP, CLO & CPO | Sell | — | — |
| 2026-02-12 | Jenny Herman | CAO | Sell | — | — |
| 2026-02-11 | Robert Lorne Abel | See Remarks | Sell | — | — |
| 2025-10-17 | Margaret Dugan | Chief Medical Officer | Sell | — | — |
| 2025-06-20 | ARUN OBEROI | Director | A | — | — |
| 2025-06-20 | Nancy Thornberry | Director | A | — | — |
| 2025-06-20 | Gary Sender | Director | A | — | — |
| 2025-06-20 | Michael Lynton | Director | A | — | — |
| 2025-06-20 | Richard Friesner | Director | A | — | — |
| 2025-06-20 | Bridget A van Kralingen | Director | A | — | — |
| 2025-06-20 | Jeffrey Chodakewitz | Director | A | — | — |
| 2025-06-20 | Rosana Kapeller-Libermann | Director | A | — | — |
| 2025-06-20 | GARY L GINSBERG | Director | A | — | — |
| 2025-05-29 | Mannix Vartan Aklian | See Remarks | A | — | — |
| 2025-05-22 | Rachit Jain | EVP & CFO | A | — | — |
| 2025-04-15 | Karen Akinsanya | President of R&D, Therapeutics | MIXED | — | — |
| 2025-03-10 | Bridget A van Kralingen | Director | A | — | — |
| 2025-03-07 | Jenny Herman | SVP & Controller | Sell | — | — |
| 2025-03-04 | Robert Lorne Abel | See Remarks | A | — | — |
| 2025-03-04 | Karen Akinsanya | President of R&D, Therapeutics | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,981,664 | — |
| — | 10%+ Owner | 6,245,181 | — |
| — | 10%+ Owner | 6,115,028 | — |
| — | Director | 705,917 | — |
| — | President & CEO | 330,824 | — |
| — | 10%+ Owner | 250,000 | — |
| — | EVP & Chief Business Officer | 149,882 | — |
| — | EVP & Managing Director | 134,442 | — |
| — | EVP, CTO & COO, Software | 89,241 | — |
| — | See Remarks | 69,956 | — |
| — | See Remarks | 55,897 | — |
| — | EVP, CLO & CPO | 52,683 | — |
| — | EVP & CFO | 50,877 | — |
| — | CAO | 34,804 | — |
| — | See Remarks | 31,193 | — |
| — | Director | 25,388 | — |
| — | Director | 25,388 | — |
| — | Director | 25,388 | — |
| — | Director | 25,388 | — |
| — | Director | 25,388 | — |
| — | Director | 25,388 | — |
| — | Director | 25,388 | — |
| — | EVP & CIO | 24,867 | — |
| — | Chief Medical Officer | 24,574 | — |
| — | Director | 19,640 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SDGR quote page; the site-wide leaderboard is on the insider transactions hub.